HCPLive Network

Three New Treatments Show Promise for Parkinson's Disease

FRIDAY, March 15 (HealthDay News) -- Three new treatments show promise for patients with Parkinson's disease, according to three studies to be presented at the annual meeting of the American Academy of Neurology, held from March 16 to 23 in San Diego.

Stuart Isaacson, MD, from the University of South Florida, in Tampa, and colleagues randomized 225 patients with Parkinson's disease to receive placebo or droxidopa, an oral pro-drug converted to norepinephrine, for an eight-week treatment period. The researchers found that, at week one, patients receiving droxidopa experienced significant improvement in dizziness/lightheadedness, with a trend toward improvement at week eight. There was a significant improvement in standing systolic blood pressure at week one with droxidopa, and a numerical improvement at week eight.

C. Warren Olanow, MD, from the Mount Sinai School of Medicine, in New York City, and colleagues randomized 337 patients with stable dosages of levodopa to tozadenant (60, 120, 180, or 240 mg twice daily) or placebo. The researchers found that patients in the 120 mg and 180 mg tozadenant groups experienced significant reductions in OFF time at 12 weeks, compared with baseline, with no increase in ON time with troublesome dyskinesia. In a third study, Robert A. Hauser, MD, of the University of South Florida, in Tampa, and colleagues found that, for patients receiving dopamine agonist monotherapy with suboptimal symptom control, treatment with add-on rasagiline resulted in a significant improvement in the Unified Parkinson's Disease Rating Scale (UPDRS) score and in UPDRS-motor scores compared with placebo.

"All of these treatments are promising news for people with Parkinson's disease, which is the second most common neurodegenerative disease after Alzheimer's disease," Hauser said in a statement.

The first, second, and third studies were funded by Chelsea Therapeutics, Biotie Therapies, and Teva Pharmaceuticals, respectively.

Abstract - Isaacson
Abstract - Olanow
Abstract - Hauser
More Information

Copyright © 2013 HealthDay. All rights reserved.

Further Reading
Monitoring patients’ own intestinal immune responses, researchers at Yale University have identified some of the bacterial culprits driving inflammatory bowel diseases (IBD) such as Crohn’s disease and ulcerative colitis.
Having regular family meals may help protect teens from the harmful mental health effects of "cyberbullying," a new study suggests. The study was published online Sept. 1 in JAMA Pediatrics.
As national and international health agencies and other groups shift their focus during the current outbreak of the Ebola virus from treatment of those patients with the virus to preventing further large scale events, a team of researchers has reported some success in looking at how Ebola compromises an infected person’s immune system.
Attention-deficit/hyperactivity disorder stimulant treatment in children is not associated with significant changes in growth, according to a study published online Sept. 1 in Pediatrics.
Patients who do not have coronary artery disease but have fat around their hearts appear more likely to develop atherosclerosis, a team of researchers in Germany found.
The leading cause of cancer related deaths in both men and women is lung cancer. The 5-year survival rate of lung cancer is only 16%, as 75% of patients with lung cancer are presented with symptoms of advanced disease.
Progress has been made toward widespread adoption of electronic health records, although there are still barriers to adoption of advanced use of EHRs, according to a report published by the Robert Wood Johnson Foundation.
More Reading
Monitoring patients’ own intestinal immune responses, researchers at Yale University have identified some of the bacterial culprits driving inflammatory bowel diseases (IBD) such as Crohn’s disease and ulcerative colitis.